Suppr超能文献

局部晚期宫颈癌患者接受放化疗后行根治性手术的病理残留肿瘤的临床影响:一项大型多中心回顾性研究。

Clinical Impact of Pathologic Residual Tumor in Locally Advanced Cervical Cancer Patients Managed by Chemoradiotherapy Followed by Radical Surgery: A Large, Multicenter, Retrospective Study.

机构信息

UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.

Istituto di Ginecologia e Ostetricia, Università Cattolica del Sacro Cuore, Rome, Italy.

出版信息

Ann Surg Oncol. 2022 Aug;29(8):4806-4814. doi: 10.1245/s10434-022-11583-4. Epub 2022 Mar 30.

Abstract

BACKGROUND

Exclusive chemoradiation (E-CT/RT) represents the standard of treatment for locally advanced cervical cancer (LACC). Chemoradiation (CT/RT) followed by radical surgery (RS) may play a role for patients with a suboptimal response to CT/RT or in low-income countries with limited access to radiotherapy. Histologic assessment of residual tumor after CT/RT and RS allows accurate definition of prognostic categories.

METHODS

Data on patients with FIGO stages 1B2 to 4A cervical cancer managed by CT/RT and RS from June 1996 to March 2020 were retrospectively analyzed. Pathologic response on the cervix was defined as complete (pCR), microscopic (persistent tumor foci ≤ 3 mm) (pmicroR), or macroscopic (persistent tumor foci > 3 mm) (pmacroR). Lymph node (LN) residual tumor was classified as absent or present.

RESULTS

The 701 patients in this study underwent CT/RT and RS. Of the 701 patients, 293 (41.8%) had pCR, 188 (26.8%) had pmicroR, and 220 (31.4%) had pMacroR. Residual tumor was found in the pelvic lymph nodes of 66 (9.4%) patients and the aortic lymph nodes of 29 (4.1%) patients. The 5-year DFS and OS were respectively 86.6% and 92.5% in the pCR cases, 80.3% and 89.1% in the pmicroR cases, and 56.2% and 68.8% in the pmacroR cases. Among the patients with lymph node residual tumor, the 5-year DFS and OS were respectively 16.7% and 40% in the pCR cases, 35.4% and 53.3% in the pmicroR cases, and 31.7% and 31.1% in the pmacroR cases. Cervical residual tumor,, positive pelvic LNs, and positive aortic LNs were associated with worse DFS and OS in both the uni- and multivariate analyses.

CONCLUSIONS

Persistence of pathologic residual tumor on the cervix and LNs after CT/RT are reliable predictors of survival for LACC patients undergoing CT/RT and adjuvant surgery.

摘要

背景

单纯化疗加放疗(E-CT/RT)是局部晚期宫颈癌(LACC)的标准治疗方法。对于对 CT/RT 反应不佳的患者,或在放疗资源有限的低收入国家,可在化疗加放疗(CT/RT)后进行根治性手术(RS)。CT/RT 和 RS 后对残余肿瘤的组织学评估可准确定义预后类别。

方法

对 1996 年 6 月至 2020 年 3 月期间接受 CT/RT 和 RS 治疗的 FIGO 分期为 1B2 至 4A 的宫颈癌患者的数据进行回顾性分析。宫颈部位的病理反应定义为完全(pCR)、显微镜下(残留肿瘤灶≤3mm)(pmicroR)或肉眼(残留肿瘤灶>3mm)(pmacroR)。淋巴结(LN)残余肿瘤分为无或有。

结果

本研究 701 例患者接受 CT/RT 和 RS 治疗。701 例患者中,293 例(41.8%)获得 pCR,188 例(26.8%)获得 pmicroR,220 例(31.4%)获得 pMacroR。66 例(9.4%)患者盆腔淋巴结和 29 例(4.1%)患者主动脉淋巴结有残余肿瘤。pCR 患者的 5 年无病生存率(DFS)和总生存率(OS)分别为 86.6%和 92.5%,pmicroR 患者分别为 80.3%和 89.1%,pmacroR 患者分别为 56.2%和 68.8%。在有淋巴结残余肿瘤的患者中,pCR 患者的 5 年 DFS 和 OS 分别为 16.7%和 40%,pmicroR 患者分别为 35.4%和 53.3%,pmacroR 患者分别为 31.7%和 31.1%。宫颈残余肿瘤、盆腔淋巴结阳性和主动脉淋巴结阳性在单变量和多变量分析中均与 LACC 患者 CT/RT 后辅助手术的 DFS 和 OS 较差相关。

结论

CT/RT 后宫颈和淋巴结残余肿瘤的病理持续存在是接受 CT/RT 和辅助手术的 LACC 患者生存的可靠预测因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验